Interferon Lambda as a Potential New Therapeutic for Hepatitis C

Interferon lambdas (IFN-gamma) are Type III interferons with biological activity, including induction of antiviral genes, similar to Type I IENs, but signal through a distinct receptor complex. The expression pattern for the IFN-gamma receptor is more cell specific than the widely distributed IFN-alpha receptor, suggesting in vivo, IFN-gamma may have fewer side effects than IFN-alpha, such as less hematologic toxicities. A PEGylated form of IFN-gamma. (PEG-rIL-29) was well tolerated in animals and did not result in hematologic toxicity. Clinical data from initial studies of PEG-rIL-29 has demonstrated antiviral effects in patients with hepatitis C without producing hematologic toxicity. These preclinical and early clinical data support PEG-rIL-29 as a potential new therapeutic agent for treatment of patients with hepatitis C.